Arbutus Biopharma Corp (NASDAQ:ABUS) has a beta value of 1.91 and has seen 2.05 million shares traded in the recent trading session. The company, currently valued at $802.30M, closed the recent trade at $4.25 per share which meant it gained $0.14 on the day or 3.40% during that session. The ABUS stock price is -11.06% off its 52-week high price of $4.72 and 60.24% above the 52-week low of $1.69. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.67 million shares traded. The 3-month trading volume is 1.10 million shares.
The consensus among analysts is that Arbutus Biopharma Corp (ABUS) is Buy stock at the moment, with a recommendation rating of 1.40. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.09.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Arbutus Biopharma Corp (NASDAQ:ABUS) trade information
Sporting 3.40% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the ABUS stock price touched $4.25 or saw a rise of 1.85%. Year-to-date, Arbutus Biopharma Corp shares have moved 70.00%, while the 5-day performance has seen it change 13.03%. Over the past 30 days, the shares of Arbutus Biopharma Corp (NASDAQ:ABUS) have changed 4.16%. Short interest in the company has seen 7.36 million shares shorted with days to cover at 4.24.
Wall Street analysts have a consensus price target for the stock at $8.5, which means that the shares’ value could jump 50.0% from the levels at last check today. The projected low price target is $8.5 while the price target rests at a high of $8.5. In that case, then, we find that the latest price level in today’s session is -100.0% off the targeted high while a plunge would see the stock gain -100.0% from the levels at last check today.
Arbutus Biopharma Corp (ABUS) estimates and forecasts
Figures show that Arbutus Biopharma Corp shares have underperformed across the wider relevant industry. The company’s shares have gained 52.87% over the past 6 months, with this year growth rate of 13.64%, compared to 17.40% for the industry. Revenue growth from the last financial year stood is estimated to be -60.90%.
5 analysts offering their estimates for the company have set an average revenue estimate of 1.86M for the current quarter. 5 have an estimated revenue figure of 1.95M for the next ending quarter. Year-ago sales stood 4.66M and 2.15M respectively for this quarter and the next, and analysts expect sales will shrink by -60.10% for the current quarter and -60.90% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 18.41% over the past 5 years.
ABUS Dividends
Arbutus Biopharma Corp is expected to release its next earnings report on 2024-Nov-05 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Arbutus Biopharma Corp (NASDAQ:ABUS)’s Major holders
Insiders own 22.30% of the company shares, while shares held by institutions stand at 51.62% with a share float percentage of 66.44%. Investors are also buoyed by the number of investors in a company, with Arbutus Biopharma Corp having a total of 176.0 institutions that hold shares in the company. The top two institutional holders are MORGAN STANLEY with over 20.96 million shares worth more than $64.77 million. As of 2024-06-30, MORGAN STANLEY held 11.9346% of shares outstanding.
The other major institutional holder is WHITEFORT CAPITAL MANAGEMENT, LP, with the holding of over 12.87 million shares as of 2024-06-30. The firm’s total holdings are worth over $39.76 million and represent 7.3269% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Morgan Stanley Insight Fund and Vanguard Total Stock Market Index Fund. As of Jun 30, 2024, the former fund manager holds about 2.24% shares in the company for having 4.24 shares of worth $17.73 million while later fund manager owns 3.88 shares of worth $16.22 million as of Jun 30, 2024, which makes it owner of about 2.05% of company’s outstanding stock.
